U.S. Markets open in 4 hrs 54 mins

Cempra, Inc. (CEMP)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
4.55+0.30 (+7.06%)
At close: 4:00PM EDT
People also watch
TTPHESPRFOLDCLVSPTCT
  • We should be getting some news from the FDA very soon on Soli trial.
  • Well, today was the day!! Parabolic SAR now positive on the weekly chart for the first time since May 2016. Last time this happened CEMP went up about 10 bucks over six months. This should create some much needed upward lift. Good luck longs!
  • 37,000 shares bought at closing today.
  • pop has alot to do sudden biotech boom but it will soar with any announcement of solithromycin curing CARP. i wud hold this
  • CEMP is up 10.47% to 4.70
  • Wow what's going on? Up huge
  • go cemp go....still holding and buying more....
  • Nice move and held the 50DMA - watch the 200DMA at 4.09 - if crosses should be some nice gains just on technical #$%$ and no real news ha
  • Alpha No News...

    Rival got news...

    lol

    A1
  • go
  • go...buy buy buy...It's up from here..
  • BK or Offering...

    As they just burn through cash...

    GL

    A1
  • If Gabelli has a sell on the stock, then that means they sold their entire position in the stock, right?
  • CEMP appears to suggest upside opportunity. Yo you should really check out awe.some.stock.s, they seem on point with their stocks.
  • Cempra doing a presentation today.Perhaps some insight on Taksta approval under Cures Act
  • CEMP is about to POP. The Parabolic SAR indicator on the weekly chart is about to go positive in a BIG way. Last time it went positive we were trading at about 20 bucks a share. Things are looking extremely positive for upward movement from a technical perspective. Good luck longs!
  • Sell Rating Just Came Out---Smart Consensus...

    GL

    A1
  • Its like buying JAZZ at $1 a few years ago now trading at $151
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • My guess is that CEMP is due for a pullback in the short-run. Ive been struggling with this stock lately. Some of my other trades have been from awesom-eSTOCKS which are working out pretty well.
  • I would think if the merits of solithera were so high and the need for new antibiotics so strong that it would take only a mediocre management team to bring it to market